Document:

Exhibit
10.7.2

 

AMENDMENT

TO 

LICENSE
AGREEMENT 

between
The South Carolina Research Foundation 

and
NephroGenex, Inc. (assignee of BioStratum Incorporated)

 

This
Amendment to the License Agreement ("First Amendment") is made effective as of the 20th day of June, 2011 (“First
Amendment Effective Date”) by and between The South Carolina Research Foundation (“SCRF”) and NephroGenex, Inc.,
a Delaware corporation (“NephroGenex”) and assignee of BioStratum Incorporated (“LICENSEE”).

 

SCRF
and LICENSEE entered into a License Agreement, dated August 27, 2004 (the “Agreement”). The Parties wish to amend
the Agreement in accordance with Article 15-11 of such Agreement, and agree that the Agreement is hereby amended as set forth
below. Capitalized terms used in this Amendment that are not otherwise defined herein, shall have the respective meanings set
forth in the Agreement.

 

Certain
terms of the License Agreement entered into between the South Carolina Research Foundation (SCRF) and LICENSEE on August, 27,
2004 are amended and replaced as follows:

 

Amended
Article 4.1.B

 

Annual
License Fees shall be due in the amounts listed below, with the first such Annual License Fee being due and payable on January
1, 2006 and each succeeding Annual License Fee being due and payable on January 1 of each year thereafter during the TERM of this
Agreement.

 

	 	2006-2008	$30,000
	 	2009-10	$60,000
	 	2011	$20,000
    due 6/30/2011, $42,000 due 12/31/2011
	 	2012	$60,000
	 	2013
    and after	$120,000

 

Annual
License Fees shall be due and payable as long as LICENSEE is actively marketing or has an active sublicense for Pyridorin. Annual
License Fees paid each year shall be creditable only against Licensed Product Sublicense upfront fees and milestone payments (defined
in Article 4-1.C. and 4-1.E., respectively) earned and payable in the same calendar year.

 

Scope
of Amendment. This Amendment supersedes all proposals, oral or written, all negotiations, conversations, or discussions between
or among parties relating to the subject matter of this Amendment and all past dealing or industry custom. This Amendment shall
be integrated in and form part of the Agreement upon execution. All terms and conditions of the Agreement shall remain unchanged
except as modified in this Amendment; and the terms of the Agreement, as modified by this Amendment, are hereby ratified and confirmed.
Where the terms of the Agreement conflict with those of this Amendment, however, the terms of this Amendment shall control. This

 

    	 

    	 

    

  

Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same agreement.

 

Termination
of this Amendment.  If this Amendment is not signed within fifteen (15) business days after receipt, then the Amendment and
its terms shall become null and void. Also, if the twenty thousand dollar ($20,000) payment is not received within fifteen (15)
business days after receipt, then the Amendment and its terms shall become null and void.

 

NOTICES,
PAYMENT, AND OTHER COMMUNICATIONS

 

Any
payment, notice or other communication required or permitted to be made or given to either Party hereto pursuant to this Agreement
shall be sufficiently made or given on the date of mailing if sent to such Party by certified United States Postal Service Express
Mail, or by utilizing an express courier service (such as Federal Express, DHL, etc.), addressed to it at the address set forth
below, or to such other address as the recipient shall have designated by written notice given to the other Party as follows:

 

In
the case of SCRF:

 

South
Carolina Research Foundation

Intellectual
Property Management Office

901
Sumter St., Suite 512

Columbia,
South Carolina 29208

Attn:
Director

 

In
the Case of NephroGenex:

 

Bob
Peterson

Vice
President of Operations

NephroGenex,
Inc.

104
Carnegie Center, Suite 214

Princeton,
NJ 08540

Office:
(609) 986-1781

Cell:
(609) 216-3045

Peterson@nephrogenex.com

 

Payments
may be made by wire transfer rather than by certified mail. If payment is made by wire transfer, written notice that payment was
made by wire transfer must be made in accordance with the provisions of. Wire transfers should be made to the following account:

 

Name
on Account:   

Account
Number:  

Routing
Number:   

 

    	 

    	 

    

 

IN
WITNESS WHEREOF this Amendment has been executed as of the Amendment Effective Date by the parties hereto by their respective
duly authorized representatives.

 

	SOUTH
    CAROLINA

RESEARCH FOUNDATION	 	NEPHROGENEX,
    INC.
	 	 	 
	By:	/s/
    Chad Hardaway	 	By:	/s/
    J. Wesley Fox
	 	 	 	 	 
	Name:
    	Chad
    Hardaway	 	Name:	J.
    Wesley Fox
	 	 	 	 	 
	Title:
    	Associate
    Director of Licensing	 	Title:	President
    and CEO
	 	 	 	 	 
	Date:	 June
    21, 2011	 	Date:	June
    20, 2011Exhibit
10.7.3

 

AMENDMENT

TO

LICENSE
AGREEMENT

between
The South Carolina Research Foundation

and NephroGenex,
Inc. (assignee of BioStratum Incorporated)

 

This Amendment
to the License Agreement (“Second Amendment”) is made effective as of the 2nd day of April, 2012 (“Second Amendment
Effective Date”) by and between The South Carolina Research Foundation (“SCRF”) and NephroGenex, Inc., a Delaware
corporation (“NephroGenex”) and assignee of BioStratum Incorporated (“LICENSEE”).

 

SCRF and LICENSEE
entered into a License Agreement, dated August 27, 2004 (the “Agreement”). The Parties wish to amend the Agreement
in accordance with Article 15-11 of such Agreement, and agree that the Agreement is hereby amended as set forth below. Capitalized
terms used in this Amendment that are not otherwise defined herein, shall have the respective meanings set forth in the Agreement.

 

Certain terms
of the License Agreement entered into between the South Carolina Research Foundation (SCRF) and LICENSEE on August, 27, 2004 are
amended and replaced as follows:

 

Amended Article
4.1.B

 

Annual License
Fees shall be due in the amounts listed below, with the first such Annual License Fee being due and payable on January 1, 2006
and each succeeding Annual License Fee being due and payable on January 1 of each year thereafter during the TERM of this Agreement.

 

	 	2006-2008	$30,000
	 	2009-10	$60,000
	 	2011	$20,000 due 6/30/2011, $42,000 due 12/31/2011
	 	2012	$10,000 due 4/15/2012, $52,000 due 12/31/2012
	 	2013 and after	$120,000

 

Annual
License Fees shall be due and payable as long as LICENSEE is actively marketing or has an active sublicense for Pyridorin. Annual
License Fees paid each year shall be creditable only against Licensed Product Sublicense upfront fees and milestone payments (defined
in Article 4-1.C. and 4-1.E., respectively) earned and payable in the same calendar year.

 

Scope
of Amendment. This Amendment supersedes all proposals, oral or written, all negotiations, conversations, or
discussions between or among parties relating to the subject matter of this Amendment and all past dealing or industry
custom. This Amendment shall be integrated in and form part of the Agreement upon execution. All terms and conditions of the
Agreement shall remain unchanged except as modified in this Amendment; and the terms of the Agreement, as modified by this
Amendment, are hereby ratified and confirmed. Where the terms of the Agreement conflict with those of this Amendment,
however, the terms of this Amendment shall control. This

 

    	 

    	 

    

 

Amendment may
be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same agreement.

 

Termination
of this Amendment.  If this Amendment is not signed within fifteen (15) business days after receipt, then the Amendment and
its terms shall become null and void. Also, if the ten thousand dollar ($10,000) payment is not received within fifteen (15) business
days after receipt, then the Amendment and its terms shall become null and void.

 

NOTICES,
PAYMENT, AND OTHER COMMUNICATIONS

 

Any payment,
notice or other communication required or permitted to be made or given to either Party hereto pursuant to this Agreement shall
be sufficiently made or given on the date of mailing if sent to such Party by certified United States Postal Service Express Mail,
or by utilizing an express courier service (such as Federal Express, DHL, etc.), addressed to it at the address set forth below,
or to such other address as the recipient shall have designated by written notice given to the other Party as follows:

 

In
the case of SCRF:

 

South Carolina
Research Foundation

Intellectual Property
Management Office

901 Sumter St.,
Suite 512

Columbia, South
Carolina 29208

Attn: Director

 

In the Case of
NephroGenex:

 

Bob Peterson

Vice President
of Operations

NephroGenex, Inc.

4401 Research
Commons Building, Suite 290

79 T.W. Alexander
Drive

P.O. Box 14188

Research Triangle
Park, NC 27709-4188

Office: (609)
986-1788

Cell: (609) 216-3045

peterson@nephrogenex.com

 

Payments may
be made by wire transfer rather than by certified mail. If payment is made by wire transfer, written notice that payment was made
by wire transfer must be made in accordance with the provisions of. Wire transfers should be made to the following account:

 

Name on Account:
  

Account Number:
 

Routing Number:
  

 

    	 

    	 

    

 

 

IN WITNESS
WHEREOF this Amendment has been executed as of the Amendment Effective Date by the parties hereto by their respective duly authorized
representatives.

 

	SOUTH CAROLINA

RESEARCH FOUNDATION	 	NEPHROGENEX, INC.
	 	 	 
	By: 	/s/ Chad Hardaway	 	By:	/s/ Bob Peterson
	 	 	 	 	 
	Name:
	Chad Hardaway	 	Name: 	Bob Peterson
	 	 	 	 	 
	Title: 	Associate Director of Licensing	 	Title: 	Vice President, Operations
	 	 	 	 	 
	Date: 	4/10/2012	 	Date: 	4/2/2012

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]